Clinical Trials · NCT06020495

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia

Name: Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 3Desmopressin

Phase: Phase 3
Recruitment status: Recruiting
Sponsor: Assistance Publique - Hôpitaux de Paris
Enrollment: 260
Start date: Dec 2024
Locations: 12 sites, France
Primary endpoint: reduced occurrence of overcorrection of serum sodium concentration (SNa) in the first 48 hours after randomization

View Desmopressin compound reference